Human VEGF Receptor 2 ELISA Kit (RMEK-0153009)
Cat. No.: RMEK-0153009
Category: ELISA Kits
INQUIRY
1 x 96 tests
Human VEGF Receptor 2 ELISA Kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of VEGF Receptor 2 protein in cell culture supernatant, serum, cit plasma, edta plasma, and hep plasma. The technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time.
Product Features
| Species Reactivity | Human |
|---|---|
| Detection Method | Colorimetric |
| Assay Duration | One step assay |
| Assay Time | 1.5 h |
| Assay Type | Sandwich (quantitative) |
| Precision | Intra-Assay-Human Serum-8-2.5%; Inter-Assay-Human Serum-3-5.8% |
| Sensitivity | 10 pg/mL |
| Range | 117 pg/mL - 7500 pg/mL |
| Sample Type | Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum |
| Recovery | Cell culture supernatant-97-95% - 98%; Serum-96-94% - 97%; Hep Plasma-97-95% - 99%; EDTA Plasma-95-89% - 98%; Cit plasma-114-109% - 122% |
| Key Features | One-wash 90 minute protocol; Sensitivity: 10 pg/mL; Range: 117 pg/mL - 7500 pg/mL; Sample type: Cell culture supernatant, Cit plasma, EDTA Plasma, Hep Plasma, Serum; Detection method: Colorimetric; Assay type: Sandwich (quantitative); Reacts with: Human |
Target Information
| Target Symbol | VEGF Receptor 2 |
|---|---|
| Function | Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. |
| Cellular Localization | Membrane. |
| Post-transcriptional Modifications | Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. |
| Involvement in Disease | Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI). HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. |
Storage & Shipping
| Storage | Store at 2-8°C |
|---|---|
| Shipping | Gel Packs |
| Stability | The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. |
For research use only. Not for clinical use.
